Sep 23, 2026 7:33am EDT Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Sep 16, 2026 7:30am EDT Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Sep 08, 2026 9:00am EDT Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 20, 2026 8:52am EDT Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Aug 17, 2026 8:52am EDT Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Aug 13, 2026 8:00am EDT Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Aug 10, 2026 8:47am EDT Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
Jul 22, 2026 8:39am EDT New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
Jul 16, 2026 8:48am EDT Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
